chrisvoncsefalvay/vaers-outcomes huggingface dataset:
I woke up Saturday morning and both eyeballs were hurting. I had sensitivity to all light.  Hurting felt like a migraine in the front of my forehead. Pain with touch when washing my face or applying a cool compress.  Took Tylenol and it did not improve the pain.
Moderate redness and swelling at (R) upper arm at site of Tdap vaccine. Mildly tender to palpation. Seen on 7/14/15.
Small Lump at the Injection Site months after the injection; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE MASS (Small Lump at the Injection Site months after the injection) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In 2021, the patient experienced VACCINATION SITE MASS (Small Lump at the Injection Site months after the injection). At the time of the report, VACCINATION SITE MASS (Small Lump at the Injection Site months after the injection) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant product use was not provided by the reporter.  Treatment information was not provided.
3 Red pox on chest 1/27 - or 1/29, 15 papule vesicles on trunk, chin forehead also with URI and conjunctivitis - Polytrim.
extreme muscle ache.  fever.  Excruciating back pain. loss of appetitie.  flu like symtoms.  Worst pain all over my body
PATIENT REQUESTED THE PFIZER BIVALENT BOOSTER BUT WAS GIVEN THE REGULAR PFIZER VACCINE. THE PATIENT EXPERIENCED NO ADVERSE EFFECTS.
Muscle/tissue atrophy at injection site almost immediately apparent - after 5 months approximately has not resolved.  Patient had Kenalog injection 2 days prior at another injection site. This is in follow-up report(s) previously submitted on 9/15/2008. Intial and follow-up inforamtion has been recieved froma a nurse practitioner concerning a 11 year old female with no pertinent medical history or history of drug reactions or drug allergies who on 30-OCT-2007 was vaccinated witht he first does of GRADASIL. On aaproximately 03-MAR-2008, "two days prior to" the second vacciantion of GRADASIL, the patient had recieved triamcinolicne acetonide injrction in the gluteal area, "another injection site", for the treatment of allergian. On 05-MAR-2008 the patient was vaccianted intramuscularly in theleft arm woth the second 0.5ml dose of GRADASIL (lot no. 655604/0052X). Concomitant therapy included drospirenous (+) ethinyl entradiol, loratadine and imphatamine espartate.amphetamineSO4/dex. On the same day, "almost immediately after her second immunization", the patient developed pain and muscle tissue atrophy at the injection site. On 01-AUG-2008, the patient was vaccinated witht he third dose of GRADASIL. As of 01-AUG-08, it was reportedthat the patient was recovering from the injection site pain. As of 08-SEP-2008, it was reported that muscle tissue athrophy at the injection site still persisted "five months later". The patient sought unspecified medical attention via office visist. Muscle tissue athrophy at the injection site was considered to be disabling and pther important medical event. Additional information is not expected.
48 hours after Iz-MENVEO presented in office with 4-5 cm oval red, indurated area with expanding area of redness beyond marked area of initial redness treated for cellulitis with KEFLEX.
This spontaneous prospective pregnancy report was received from a medical assistant refers to a 18 year old female patient. The medical history, concurrent conditions and concomitant medications were not reported. On 18-AUG-2017, the patient was vaccinated with GARDASIL 9 lot # N000326, 14-OCT-2019, intramuscular, dose 1 for prophylaxis. On 14-FEB-2018, the patient was vaccinated with GARDASIL 9,intramuscular, lot # N021572, 01-MAY-2020 dose 2 for prophylaxis. On 13-JUL-2018, the patient was vaccinated with GARDASIL 9 intramuscular, lot # N023828, 25-JUN-2020 dose 3 for prophylaxis. Other suspect therapies included BEXSERO on 13-JUL-2018. The patient's mother reported that patient was 7 months pregnant. The pregnancy was discovered a few weeks ago and the patient had seen an unspecified gynecologist. The ultrasound of the patient was performed and it did not show any fetal abnormalities. The approximated LMP (last menstrual period) was 06-JAN-2018, Estimated date of delivery is on 13-OCT-2018. Date of conception was 20-JAN-2018. There was no treatment rendered for the event. The patient sought medical attention.
Started having sinus problems and a cough. Took a home COVID-19 test and was positive. Spoke to doctor but wasn't prescribed anything. Still recovering.
I could hear and feel my heart pounding so hard that it felt like it was going to pop out. Following day I had chest pains that subsided after a day. Third day after vaccine, I started to experience vision problems that made it hard to focus and vision was off, and it was hard to think straight.
Pt recvd 2 doses of Hep B & 1 dose of Engerix-B 7JUN92 & 8PM 7JUN92 devel aching all over, & fever which has resolved; 8JUN92 devel edema of ankles, feet & lower extremities, which persists; feels ok x/for edema;
received vaccines after a temperature excursion; This non-serious case was reported by a other health professional and described the occurrence of incorrect storage of drug in a 1-year-old patient who received Hepatitis A vaccine (batch number 3397T) for prophylaxis.   On 28-FEB-2023, the patient received the 2nd dose of Hepatitis A vaccine. On an unknown date, an unknown time after receiving Hepatitis A vaccine, the patient experienced incorrect storage of drug (Verbatim: received vaccines after a temperature excursion). The outcome of the incorrect storage of drug was unknown.   Additional Information: GSK receipt date: 14-APR-2023 The reporter consented to follow-up. This case is for one of 119 patients, reported by same reporter. The patient received unstable vaccine after a temperature excursion, which led to incorrect storage of drug; Sender's Comments:  US-GSK-US2023054677:same reporter US-GSK-US2023AMR055743:same reporter
waves of flushing through out her body; severe dry mouth; nausea; elevated heart rate into 120s; panic attack; This is a spontaneous report from a contactable consumer. A female patient of an unspecified age received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration in 2020 (at 0810 her time) at single dose for immunization. The patient's medical history and concomitant medications were not reported. The reporter is a Certified Nursing Assistant (CNA) who received the Covid 19 vaccine at 0810 her time. Five minutes after receiving the vaccine (2020) she reported having three episodes of the following symptoms: waves of flushing through out her body, severe dry mouth, nausea and elevated heart rate into 120s. She denied any shortness of breath, swelling or anaphylaxis. She was treated in the Emergency Room (ER) with fluids and lorazepam (ATIVAN) and sent home. She contacted her doctor who advised she was probably having a panic attack and was told her to take lorazepam. She reported sleeping when she got home but experienced the elevated heart rate and flushing again after waking. She spoke to her doctor a second time and was told to return to the ER to be treated for the elevated heart rate. She did not go to the ER because she took more lorazepam and the HR declined into the 90's. She stated her doctor was prescribing a beta blocker for her but advised to go to the ER if her heart rate goes over 100 again. She would like to report and Adverse Event. The outcome of the events was unknown.   Information regarding lot/batch has been requested.; Sender's Comments: Based on the information available as reported at this point, a possible contributory role of the suspect products cannot be excluded for the reported event flushing, dry mouth, heart rate increased, nausea and panic attack due to temporal association.
pt received  two Moderna shots in 1/20/21 and 2/18/2021 at a different location. Came to our pharmacy on 8/07/21 for a booster and got the pfizer shot. This is outside of ACIP guideline.
Vaccine was administered subcutaneously in the back of my arm which is large.  It was not put in my deltoid. I even asked the NP if it was supposed to be a subq or IM injection and he said IM but continued to give it sub q & now I have localized swelling & pain.  He also rubbed it vigorously after injecting it.
Sleepiness, fever, chills, achy all over, headache, tightness in chest
Injection site pain, muscle aches, low grade fever, chills, large hive/ swelling at injection site onset 24 hrs s/p vaccine.. still present 2 days after and ongoing.  tylenol 500 mg taken.
Extreme brain fog, diarrhea for four weeks, light sensitivity and blurred vision, kidney pain (cycled, some days hurt some days did not), Sinus pain, swollen lymph node (right side), muscle weakness in legs, jaw and tongue tremors, complete loss of appetite, lost approximately 10 lbs in three weeks, headaches daily, difficulty concentrating, sudden onset of nervousness and depression, late period., symptoms would worsen after eating or drinking.   anti-biotics were given for two weeks, hoped it would clear up.
Patient felt dizzy after vaccine - that evening developed headache and fever, problems actualizing sentences - patient felt she was unable to walk well/having problems ambulating.
Employee reported symptoms began on Saturday, July 31st of headache, coughing, chills and body aches
2 hours after shot started getting sore throat and headache next day chest hurt throat, headache bad cough runny nose very tired. As of 10-1-10 still have slight cough and runny nose went to Dr 10-20-10 received a shot.
Information has been received from a woman concerning her daughter who was vaccinated with a dose of GARDASIL on an unspecified date. Subsequently the patient was diagnosed with cervical cancer. The reporter said it was because of the vaccine. The reporter mentioned that a doctor was running a series of tests on her daughter to find out exactly what it was or what might be the cause. At the time of the report, the outcome was unknown. Upon internal review, cervical cancer was considered to be an other important medical event. Attempts are being made to verify the existence of an identifiable patient.
Nasal Swab Test, Result Positive; Nasal Swab Test, Result Positive; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP) from product quality group. The reporter is the patient.  A 37 year-old male patient received bnt162b2 (BNT162B2), administered in arm left, administration date 11Nov2021 14:45 (Lot number: 33026BD) at the age of 37 years as dose 2, single and administered in arm left, administration date 21Aug2021 16:00 (Lot number: EW0183) as dose 1, single for covid-19 immunisation. Relevant medical history included: "Asthma" (unspecified if ongoing). Concomitant medication(s) included: ADVAIR HFA; ALBUTEROL SULFATE; OXYCODONE. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset 27Dec2021, outcome "unknown" and all described as "Nasal Swab Test, Result Positive". The patient underwent the following laboratory tests and procedures: sars-cov-2 test: (27Dec2021) positive, notes: Nasal Swab (done at urgent care); (07Jan2022) positive, notes: Nasal Swab (done at pharmacy).  Clinical course: No other vaccine taken in four weeks. No known allergies. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had been tested positive for COVID-19.
Headache, Myalgia, Fever, 2/1/21 -1315 employee began feeling "not right", light headed, nauseated, and  prickly throat. V/S is as following; 1315- BP 116/73, HR 74, O2 100% RA.  1335- BP 113-68 HR 69, 100% 98.3. 1348-BP 108/71, 74, 99% RA. She denies SOB. No swelling or rash noted.  Narrative:
Red Swollen itchy arm where shot and down to my hand. Very tired Headache  Felt like jet Lag
1 hour after receiving HPV vaccine became dizzy, skin sensation of burning and flushing all over. Nausea with SOB with talking. Generalized weakness.
Vaccine induced thrombocytopenia Continuous drop in platelets from > 200 to 6 . Platelet nadir reached on 09/09/2021 Mild echymoses  Received IVIG (1gm/kg x2 and and Dexamethasone (40 mg x4)
This spontaneous report as received from a registered nurse refers to a patient of unknown age and gender. On 22-OCT-2013, the patient was vaccinated with a last dose (third dose) of oral ROTATEQ (Lot number and expiry date were not reported), 2 milliliter (ml), orally at age of 9 months old and no adverse effect was reported. Additional information has been requested.
Initial information received on 24-Oct-2018 regarding an unsolicited valid non-serious case received from a physician. This case involves a 6 years old patient (gender not reported), who experienced sneezing, began to have itchy eyes, cough, erythema at the injection site and the patient was tested for egg allergy and that was negative/unsure if this reaction is a contraindication to her receiving the flu vaccine again, while he/she received vaccine FLUZONE QUADRIVALENT. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. Concomitant medications were not reported. On an unknown date, the patient received a dose of suspect Influenza Quadrival A-B Vaccine lot number not reported. On an unknown date, the patient developed a non-serious sneezing 30 minutes following the administration of Influenza Quadrival A-B Vaccine. On an unknown date, the patient developed a non-serious began to have itchy eyes (eye pruritus) 30 minutes following the administration of Influenza Quadrival A-B Vaccine. On an unknown date, the patient developed a non-serious cough 30 minutes following the administration of Influenza Quadrival A-B Vaccine. On an unknown date, the patient developed a non-serious erythema at the injection site (vaccination site erythema) 30 minutes following the administration of Influenza Quadrival A-B Vaccine. It was a case of contraindication to vaccination as the patient had tested for egg allergy and that was negative. It was reported that the reporter was unsure if there are other components of the vaccine that may have caused her to have localized reaction. Other relevant tests included On an unknown date, the patient was tested for egg allergy and that was negative. Final diagnosis was the patient was tested for egg allergy and that was negative/unsure if this reaction is a contraindication to her receiving the flu vaccine again, erythema at the injection site, cough, began to have itchy eyes and sneezing. It was not reported if the patient received a corrective treatment. The patient outcome is reported as Unknown for sneezing, as Unknown for began to have itchy eyes, as Unknown for cough, as Unknown for erythema at the injection site and as Not Applicable for the patient was tested for egg allergy and that was negative/unsure if this reaction is a contraindication to her receiving the flu vaccine again. Documents held by the sender: none.
pt given vax rt deltoid inflammation the size of silver dollar, 2 days p/vax redness & pain through whole arm; spread visually from deltoid to past elbow; swelling, hot to touch, unable to lift, applied ice 2 days later had a black blister
I had a really low drop in blood pressure probably like 74 over 54; I got really nauseous; I was just dehydrated; This is a spontaneous report received from a contactable consumer. The reporter is the patient.  A 61 year-old female patient received bnt162b2 (BNT162B2), administered in arm left, administration date 26Apr2021 (Lot number: EW0172) at the age of 61 years as dose 2, single for covid-19 immunisation. The patient also received unspecified Vaccine. Relevant medical history included: "High blood pressure" (unspecified if ongoing). Concomitant medication included: LOSARTAN taken for hypertension. Vaccination history included: Bnt162b2 (Dose: 1), for Covid-19 immunization; Flu vaccine 2 weeks prior to this vaccine. The following information was reported: HYPOTENSION with onset Apr2021, outcome "recovered", described as "I had a really low drop in blood pressure probably like 74 over 54"; NAUSEA (non-serious) with onset Apr2021, outcome "unknown", described as "I got really nauseous"; DEHYDRATION (non-serious) with onset Apr2021, outcome "unknown", described as "I was just dehydrated". The patient reported: "With my second shot it was not 48 hours to probably more than 48 hours I had a really low drop in blood pressure probably like 74 over 54 which is pretty concerning that went away after couple of hours but it might have been there I was just dehydrated because I got really nauseous with the second shot. The patient underwent the following laboratory tests and procedures: blood pressure measurement: (Apr2021) probably like 74 over 54.  Follow-up (25Nov2021): Follow-up attempts are completed. No further information is expected.
Patient was administered her 1st vaccine dose on 3/18/2021. She presented to the vaccination clinic on 3/25/2021 to receive 2nd dose.  She was mistakenly given her 2nd dose on 3/25/2021 which did not follow the 21 day dosing schedule.
Injection site felt itchy, became red after a couple days and raised. Feels firm to the touch. Had vesicles at one point.
Chills; pain in arm; sore aching body; headache; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 53-year-old male patient received bnt162b2 omi xbb.1.5 (COMIRNATY (2023-2024 FORMULA)), on 28Sep2023 at 11:45 as dose 6 (booster), single (Lot number: HF9275) at the age of 53 years intramuscular, in left arm for covid-19 immunisation. The patient's relevant medical history included: "high blood pressure" (unspecified if ongoing); "cholesterol" (unspecified if ongoing); "AFIB" (unspecified if ongoing); "Bees" (unspecified if ongoing); "Sulfa allergy" (unspecified if ongoing). The patient's concomitant medications were not reported. Past drug history included: Ciprofloxacin, reaction(s): "Drug Allergy"; Flu for Influenza Immunization, notes: DOSE NUMBER UNKNOWN, SINGLE; MANUFACTURER UNKNOWN. Vaccination history included: bnt162b2 (DOSE 4 (BOOSTER), SINGLE; Lot number: FH8027; Anatomical Location: Arm Left), administration date: 07Apr2022, for COVID-19 immunization, reaction(s): "Nausea", "Aches", "sore arm"; bnt162b2, bnt162b2 omi ba.4-5 (DOSE 5 (BOOSTER), SINGLE; Lot number: GJ6742, Route of Administration: Intramuscular; Anatomical Location: Arm Right), administration date: 26Oct2022, for COVID-19 immunization, reaction(s): "Body aches", "hot and cold", "knot in arm", "arm twitching", "Headache", "Nausea"; Covid-19 vaccine (DOSE 1, SINGLE; MANUFACTURER UNKNOWN), for COVID-19 immunization; Covid-19 vaccine (DOSE 2, SINGLE; MANUFACTURER UNKNOWN), for COVID-19 immunization; Covid-19 vaccine (DOSE 3 (BOOSTER), SINGLE; MANUFACTURER UNKNOWN), for COVID-19 immunization. The following information was reported: CHILLS (non-serious) with onset 28Sep2023, outcome "recovering"; HEADACHE (non-serious) with onset 28Sep2023, outcome "recovering"; PAIN IN EXTREMITY (non-serious) with onset 28Sep2023, outcome "recovering", described as "pain in arm"; PAIN (non-serious) with onset 28Sep2023, outcome "recovering", described as "sore aching body". Therapeutic measures were not taken as a result of chills, pain in extremity, pain, headache.  Additional information: The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient was not diagnosed with COVID-19 prior to vaccination. The patient had not been tested for COVID-19 since the vaccination.
Information has been received from a health professional concerning an 18 year old female with prophylaxis who on 15-NOV-2006 was vaccinated with the first dose of GARDASIL (lot # 653978/0955F) 0.5 mL, I.M. route, on 17-JAN-2007 was vaccinated with the second dose of GARDASIL (lot # 655617/1447F) 0.5 mL, I.M. route, on 23-MAY-2007 was vaccinated with the third dose of GARDASIL (lot # 657736/0389U) 0.5 mL, I.M. route. Concomitant therapy included DESOGEN. The patient received a second series of GARDASIL. On 27-OCT-2008, was vaccinated with the first dose of the second series of GARDASIL (lot # 660616/0570X) 0.5 mL, I.M. route and had a PAP test abnormal. On 20-NOV-2008, the patient had a colposcopy (results not reported). On 17-FEB-2009, was vaccinated with the second dose of the second series of GARDASIL (lot # 661531/1311X) 0.5 mL, I.M. route. On 15-JUN-2009, was vaccinated with the third dose of the second series of GARDASIL (lot #660616/0570X) 0.5 mL, I.M. route and had a PAP test abnormal. At the time of the report the outcome of the event was unknown. The patient sought unspecified medical attention.
Patient presented to the ED and was subsequently hospitalized on 3/11/2021 for acute cystitis with hematuria and acute kidney injury. Patient presented to the ED and was subsequently hospitalized on 4/19/2021 with generalized weakness and confusion. These visits are within 6 weeks of receiving COVID vaccination.
injection site soreness; low grade fever; whole body muscle soreness; fatigue; headache; malaise; This is a spontaneous report from a non-contactable healthcare professional.  A 42-years-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE), Lot# EK9231, via an unspecified route of administration on 19Jan2021 10:00 at a single dose in left arm  (Dose 1) for COVID-19 immunization.  The patient was not pregnant. The patient did not receive any other vaccine in the 4 weeks prior to COVID vaccination. Medical history included irritable bowel syndrome, herniated disc issues, and migraine. There were no known allergies. The patient was not diagnosed with COVID prior to vaccination. Concomitant medication included tramadol, colecalciferol (VITAMIN D), vitamin C, magnesium,  and probiotics. On 20Jan2021 at 14:00 , the patient experienced injection site soreness, low grade fever, whole body muscle soreness, fatigue, headache, and malaise. There was no treatment received for the events. The outcome of the events injection site soreness, low grade fever, whole body muscle soreness, fatigue, headache, and malaise was recovering. The patient was not COVID tested post-vaccination.  No follow up attempts are possible. No further information is expected.
concerned about receiving the 2nd dose; tingling all over her body day"; This spontaneous case was reported by a consumer and describes the occurrence of PARAESTHESIA (tingling all over her body day") and DISCOMFORT (concerned about receiving the 2nd dose) in a 68-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 016M20A) for COVID-19 vaccination.     The patient's past medical history included No adverse event.    On 11-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 12-Feb-2021, the patient experienced PARAESTHESIA (tingling all over her body day"). On 08-Mar-2021, the patient experienced DISCOMFORT (concerned about receiving the 2nd dose). At the time of the report, PARAESTHESIA (tingling all over her body day") and DISCOMFORT (concerned about receiving the 2nd dose) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No relevant concomitant medications were reported. No treatment information was provided.
Erythema, swelling, tenderness at injection site.  Macular rash from neck to waist that lasted five days.  Fatigue for three days.
swollen lymph node in left arm pit started on 1/23/21; itchy, tender spot near injection site started the evening of 1/25/21; red, hot, slightly itchy rash developed the morning of 1/26/21 and grew bigger on 1/27/21.  On 1/28/21, rash became less red and did not grow as much.  Took Benadryll, Zyrtec and Tylenol to help with symptoms.  Lymph node seems to have resolved itself now too.